2A5U

Crystal Structure of human PI3Kgamma complexed with AS605240


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.7 Å
  • R-Value Free: 0.351 
  • R-Value Work: 0.279 

wwPDB Validation 3D Report Full Report


This is version 1.3 of the entry. See complete history

Literature

Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis

Camps, M.Ruckle, T.Ji, H.Ardissone, V.Rintelen, F.Shaw, J.Ferrandi, C.Chabert, C.Gillieron, C.Francon, B.Martin, T.Gretener, D.Perrin, D.Leroy, D.Vitte, P.-A.Hirsch, E.Wymann, M.P.Cirillo, R.Schwarz, M.K.Rommel, C.

(2005) NAT.MED. (N.Y.) 11: 936-943

  • DOI: 10.1038/nm1284
  • Primary Citation of Related Structures:  2A4Z

  • PubMed Abstract: 
  • Phosphoinositide 3-kinases (PI3K) have long been considered promising drug targets for the treatment of inflammatory and autoimmune disorders as well as cancer and cardiovascular diseases. But the lack of specificity, isoform selectivity and poor bio ...

    Phosphoinositide 3-kinases (PI3K) have long been considered promising drug targets for the treatment of inflammatory and autoimmune disorders as well as cancer and cardiovascular diseases. But the lack of specificity, isoform selectivity and poor biopharmaceutical profile of PI3K inhibitors have so far hampered rigorous disease-relevant target validation. Here we describe the identification and development of specific, selective and orally active small-molecule inhibitors of PI3Kgamma (encoded by Pik3cg). We show that Pik3cg(-/-) mice are largely protected in mouse models of rheumatoid arthritis; this protection correlates with defective neutrophil migration, further validating PI3Kgamma as a therapeutic target. We also describe that oral treatment with a PI3Kgamma inhibitor suppresses the progression of joint inflammation and damage in two distinct mouse models of rheumatoid arthritis, reproducing the protective effects shown by Pik3cg(-/-) mice. Our results identify selective PI3Kgamma inhibitors as potential therapeutic molecules for the treatment of chronic inflammatory disorders such as rheumatoid arthritis.


    Organizational Affiliation

    Serono Pharmaceutical Research Institute, Serono International S.A., 14, Chemin des Aulx, 1228 Plan-les-Ouates, Geneva, Switzerland.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit, gamma isoform
A
966Homo sapiensGene Names: PIK3CG
EC: 2.7.11.1, 2.7.1.153
Find proteins for P48736 (Homo sapiens)
Go to Gene View: PIK3CG
Go to UniProtKB:  P48736
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
QYT
Query on QYT

Download SDF File 
Download CCD File 
A
(5E)-5-(QUINOXALIN-6-YLMETHYLENE)-1,3-THIAZOLIDINE-2,4-DIONE
5-QUINOXALIN-6-YLMETHYLENE-THIAZOLIDINE-2,4-DIONE
C12 H7 N3 O2 S
SQWZFLMPDUSYGV-POHAHGRESA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
QYTIC50: 8 - 9 nM (99) BINDINGDB
QYTIC50: 8 nM PDBBIND
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.7 Å
  • R-Value Free: 0.351 
  • R-Value Work: 0.279 
  • Space Group: C 1 2 1
Unit Cell:
Length (Å)Angle (°)
a = 140.446α = 90.00
b = 67.406β = 96.35
c = 105.971γ = 90.00
Software Package:
Software NamePurpose
PDB_EXTRACTdata extraction
CNSrefinement
CCP4data scaling
AMoREphasing
CNXrefinement
SCALAdata scaling
MOSFLMdata reduction

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Revision History 

  • Version 1.0: 2005-09-20
    Type: Initial release
  • Version 1.1: 2008-04-30
    Type: Version format compliance
  • Version 1.2: 2011-07-13
    Type: Version format compliance
  • Version 1.3: 2017-10-11
    Type: Refinement description